The information contained in this website is meant to be helpful and educational, but is not a substitute for medical advice.

Reg Charity No 1131517

Mission Statement

Terms & Conditions

Disclaimer

Copyright©2012

All rights reserved

 

 

Epictatus in the third century BC postulated that: "It is impossible to learn something that we think we already know".

 

 

Proventus.org.uk

“The Library”

Twittering On Twitter
Find Us On Facebook
Take a Look
Blog Spot

Forum

Fryers Places

Improving Life

Increasing Hope

Copaxone - Glatiramer Acetate

Thought to work both outside and inside the damage to the nervous system.It is believed to change the way the immune system reacts to Multiple Sclerosis by preventing harmful cells from developing and by stimulating beneficial cells in your body. The activated cells then enter the CNS (central nervous system) and help reduce damage at the site of lesions.

Glatiramer combines the amino acids L-alanine, L-glutamic acid, L-lysine and L-tyrosine. The mixture is similar to myelin basic protein, an important component of the myelin sheath of nerves. It is used for relapsing-remitting multiple sclerosis (RRMS).

Usually prescribed to an MS person when they are ambulant (able to walk 10 metres or more). Plus showing signs of MS symptoms that are either.

Evidence of additional lesions within the last year on their MRI scans. Or same evidence in a MS person but with a poor prognosis for other reasons.

One disabling relapse in the past year.

Two significant relapses in the past two years.

In certain circumstances an MS person experiencing Secondary - Progressive MS and are ambulant and that relapses are the cause of an increasing difficulty may be treated - advice should be obtained from their health professional.

An acute worsening of MS symptoms that is sustained for a day or more followed by an improvement of the symptoms over one to four weeks would indicate a relapse has occurred.

A worsening of MS symptoms may also be caused by:

Johnson KP, et al.Copolymer 1 reduces relapse rate and improves difficulty in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45(7):1268-1276. PubMed

Association of British Neurologists (ABN) Revised (2009) guidelines for prescribing in multiple sclerosis.London; ABN: November 2009. Download pdf File

 

Top

Side effects may occur such as:                       

 

Serious Side effects may occur such as:

 

There may be a short-term reaction immediately after injecting. The reaction may involve:

The reactions are usually mild and seldom require treatment, however in the event that any symptoms do not disappear within a short time immediately consult a health professional.

 

Report Side Effects - Site Page

 

Top